Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | Future treatment options for multiple myeloma

Karthik Ramasamy • 27 Mar 2017
BSH 2017
Multiple Myeloma

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses future treatment options for multiple myeloma at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Immunomodulatory drugs are commonly used in the treatment of multiple myeloma. The next step is combining different treatments, such as chemotherapy, steroids, and monoclonal antibodies, to achieve deeper remissions and therefore better outcomes for patients.

More from Karthik Ramasamy

1:17
Novel agents to improve outcomes for patients with multiple myeloma in the salvage setting
Karthik Ramasamy • 20 Dec 2023
2:42
Optimizing maintenance therapy in multiple myeloma: an analysis from the PREAMBLE registry
Karthik Ramasamy • 20 Dec 2023
2:05
RADAR: guiding treatment for NDMM with MRD and genetic risk
Karthik Ramasamy • 20 Dec 2023
2:25
OxCOM: monitoring monoclonal gammopathies for progression to active myeloma
Karthik Ramasamy • 20 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals